Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Q1 2021 Earnings Presentation
15 slides from Expres2ion Biotech Holding Ab's earnings presentation, May 19, 2021
Slide 1: Proteins for Life – Q1-2021 Report
Proteins for Life 19th May, 2021 Q1-2021 Report Bent U. Frandsen, CEO Keith Alexander, CFO Proteins for Life
Slide 2: Forward-looking statements and disclaimer
Forward-looking statements and disclaimer This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this pre
Slide 3: At a glance
At a glance • A Scandinavian clinical-stage biotechnology company founded in 2010 • Vision to become leader in the oncology and Infectious diseases fields • Listed in 2016 on Nasdaq First North Growth Market Stockholm • 34% ownership of AdaptVac ApS, a capsid VLP technology holder • Advantageous and
Slide 4: Broad clinical stage pipeline
Broad clinical stage pipeline Addressing high medical needs with development partner potential Pre-clinical DISEASE Project / Target Discovery Pharmacology cGMP / Tox Phase 1 Phase 2 Phase 3 Partners / Funding PREVENT-nCOV COVID-19 ABNCoV2/SARS-CoV-2 cVLP I / II Breast cancer ES2B-C001/Her2 cVLP 100
Slide 5: News flow during 1st Quarter 2021
st News flow during 1 Quarter 2021 CORONAVIRUS/COVID-19 Jan. 8th: Submission of the COUGH-1 Jan. 12th: Strong preclinical Mar. 8th: Approval and Apr. 12th: Interim safety update clinical trial application by the immunization data for the ABNCoV2 initiation of the COVID-19 on COUGH-1, the COVID-19 Pr
Slide 6: Proteins for Life
Proteins for Life
Slide 7: Q1-2021 Report
Q1-2021 Report Proteins for Life 7
Slide 8: Q1 2021 Financial results
Q1 2021 Financial results 2021 2020 2020 SEK '000s Jan-Mar Jan-Mar Jan - Dec Operating income 1,931 2,829 15,263 Loss after financial items -12,129 -5,935 -34,923 Net loss for the period -11,156 -5,234 -31,713 Earnings per share -0.40 -0.37 -1.83 Cash balance, end of period 82,806 6,194 106,832 Tota
Slide 9: Key financial developments in Q1
Key financial developments in Q1 • Net sales improved while other operating income (grant-driven) declined due to full realization of COVID-19 grant • One-time payment for the ES2B-C001 license of SEK 3.4 million (DKK 2.5 million) • Higher costs associated with pipeline projects and personnel • Lowe
Slide 10: Income statement
Income statement Group Jan - Mar Jan - Mar Jan – Dec SEK '000s 2021 2020 2020 Operating income Net sales 1,704 2,223 5,259 Other operating income 227 606 10,004 Total operating income 1,931 2,829 15,263 Operating costs Raw materials and consumables -2,632 -939 -6,102 Other external costs -6,239 -2,5
Slide 11: A note on investor mix
A note on investor mix May 27, 2021: ExpreS2ion Biotech Q1 2021 turnover for First North-listed Healthcare companies Number of investors, by country AB to be added to MSCI Global Micro Cap (Source:MSCI) (shares traded / market capitalization) 600 500 400 300 200 100 0 INTERVACC Sedana Medical Qlife
Slide 12: Proteins for Life
🗸 🗸 🗸 🗸 🗸 Proteins for Life
Slide 13: Proteins for Life – Q1-2021 Report
Proteins for Life 19th May, 2021 Q1-2021 Report Bent U. Frandsen, CEO Keith Alexander, CFO Proteins for Life
Slide 14: Appendix
Appendix Background Company Information Proteins for Life 14
Slide 15: Company structure
Company structure Focused on development of vaccines, immune therapy and diagnostics ExpreS2ion Biotech Swedish AB 2016 • AB listed in Stockholm in 2016 On NASDAQ First North [EXPRS2] • >12,000 shareholders, Market cap >EUR 100m *) ExpreS2ion Biotechnologies Danish ApS 2010 • ExpreS2 platform develo
ExpreS2ion Biotech Holding — Q1 2021 Earnings Presentation on 6ix